Drug companies unite to develop new treatment for Parkinson’s
Seven of the world’s largest pharmaceutical companies have signed up to a ground breaking consortium aimed at accelerating the development of safe and effective therapies for Parkinson’s disease.
The Critical Path for Parkinson’s consortium will bring together leading academics; industry members AbbVie, AstraZeneca, Biogen, Eli Lilly and Company, Merck Sharp and Dohme Pfizer, and UCB, and founders of the Critical Path Institute (C-Path) and Parkinson’s UK, to share data, expertise and resources to promote and develop new treatments for Parkinson’s.
Dr Arthur Roach, Director of Research at Parkinson’s UK said: “Despite significant advances in our understanding of the genetics, biochemistry and pathology of Parkinson’s, the development of new treatments has not kept pace. New treatments are desperately needed to deal with the devastating effects of this progressive condition.
“Investing in clinical trials for brain disorders currently carries a high cost and high risk of failure. As the world’s largest patient-led Parkinson’s charity, we know that people living with conditions such as Parkinson’s have often been disappointed when drugs that showed significant promise early on failed in late stage testing.
“We see the consortium as a crucial part of strategies to develop new treatments that work at the earliest stage of the condition, with the goal of slowing its progression, and eventually finding a cure.”
In 2012/13, the National Health Service spent more than £212 million on caring for people with Parkinson’s in England, with the cost of the condition in the United States approximately $25 billion per year.
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) estimated that the cost of developing a single drug was US$1.3 billion, rising from US$138 million in 1978.
“With the increase in the costs of getting a drug to market, the design of a clinical trial is a crucial part of a drug’s success,” said Diane Stephenson, Executive Director, Critical Path for Parkinson’s consortium.
“There is a strong realisation from the industry that collaboration among industry, academia, and worldwide regulatory agencies, along with the sharing of data, has the potential to create a more efficient development process. This recognition is evidenced by the fast pace at which members of this new consortium have joined.”
Parkinson’s affects 127,000 people in the United Kingdom, and approximately 7 million people worldwide.